Trajenta

Trajenta

linagliptin

Manufacturer:

Boehringer Ingelheim

Distributor:

DKSH
Concise Prescribing Info
Contents
Linagliptin
Indications/Uses
Adjunct to diet & exercise to improve glycemic control in adults w/ type 2 DM.
Dosage/Direction for Use
Administration
May be taken with or without food.
Contraindications
Special Precautions
Not to be used in patients w/ type 1 diabetes or for the treatment of diabetic ketoacidosis. Concomitant use w/ sulphonylurea or insulin (reduce dose). Discontinue use if bullous pemphigoid is suspected. Acute pancreatitis; promptly discontinue if pancreatitis is suspected. Dizziness may affect ability to drive or operate machinery. Avoid use during pregnancy. Discontinue during lactation. Not recommended in childn <18 yr. Elderly >75 yr.
Adverse Reactions
Nasopharyngitis; hypersensitivity, angioedema, urticaria; hypoglycaemia (in combination w/ metformin + sulphonylurea), hypertriglyceridaemia (in combination w/ sulphonylurea), hyperlipidaemia (in combination w/ pioglitazone); cough; pancreatitis, constipation (in combination w/ insulin), mouth ulceration; rash, bullous pemphigoid; increased wt (in combination w/ pioglitazone), lipase & amylase.
Drug Interactions
Increased AUC & Cmax w/ ritonavir. Decreased steady-state AUC & Cmax & dipeptidyl peptidase 4 inhibition at trough w/ rifampicin. Increased AUC & Cmax of simvastatin.
MIMS Class
Antidiabetic Agents
ATC Classification
A10BH05 - linagliptin ; Belongs to the class of dipeptidyl peptidase 4 (DPP-4) inhibitors. Used in the treatment of diabetes.
Presentation/Packing
Form
Trajenta FC tab 5 mg
Packing/Price
30's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Already a member? Sign in
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Already a member? Sign in